The Compound Report is an educational resource. Nothing on this site constitutes medical advice or encourages personal use of any compound. Always consult a qualified healthcare provider.

Side by side

Compound comparison

Check interactions →Open as saved/share list

Noopept (Omberacetam)

OTC · Grade C

Goals
cognition, sleep
Evidence
3 RCT / 4 animal / 2 in vitro
Routes
nasal, oral
WADA
No
FDA
Not approved
Cancer caution
none
Typical dose
—
Half-life
—
Primary mechanism
Mechanism diagram showing the compound's primary signaling pathway and downstream effects.
View full report →

J-147

Research chemical · Grade C

Goals
cognition, longevity, mitochondria
Evidence
1 RCT / 5 animal / 4 in vitro
Routes
oral
WADA
S4
FDA
Not approved
Cancer caution
caution
Typical dose
—
Half-life
—
Primary mechanism
Mechanism diagram showing the compound's primary signaling pathway and downstream effects.
View full report →

DSIP

Research chemical · Grade C

Goals
cognition, sleep
Evidence
1 RCT / 6 animal / 1 in vitro
Routes
injectable-sc, nasal
WADA
No
FDA
Not approved
Cancer caution
none
Typical dose
—
Half-life
In animal studies: the half-life appears even shorter — approximately 4-5 minutes in vivo
Primary mechanism
Mechanism diagram showing the compound's primary signaling pathway and downstream effects.
View full report →

Epitalon

Bioregulator · Grade C

Goals
cognition, sleep, longevity
Evidence
0 RCT / 5 animal / 3 in vitro
Routes
injectable-sc, nasal
WADA
No
FDA
Not approved
Cancer caution
hard-stop
Typical dose
—
Half-life
—
Primary mechanism
Mechanism diagram showing the compound's primary signaling pathway and downstream effects.
View full report →